{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:33:29Z","timestamp":1793338409748,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RD21\/0017\/0012"],"award-info":[{"award-number":["RD21\/0017\/0012"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","award":["SGR21\/01169"],"award-info":[{"award-number":["SGR21\/01169"]}],"id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["RED2022-134221-T"],"award-info":[{"award-number":["RED2022-134221-T"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010434","name":"'la Caixa' Foundation","doi-asserted-by":"publisher","award":["LCF\/PR\/SP23\/52950009"],"award-info":[{"award-number":["LCF\/PR\/SP23\/52950009"]}],"id":[{"id":"10.13039\/100010434","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["PID2023-146637OB-C22"],"award-info":[{"award-number":["PID2023-146637OB-C22"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["PID2020-119692RB-C22"],"award-info":[{"award-number":["PID2020-119692RB-C22"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jconrel.2026.115320","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T23:11:37Z","timestamp":1788045097000},"page":"115320","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"PA","title":["Position-specific polymeric-coated oncolytic adenovirus improves anti-tumor efficacy and evades neutralizing antibodies in pancreatic cancer models"],"prefix":"10.1016","volume":"399","author":[{"given":"Marc","family":"Otero-Mateo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Francesc","family":"Estrany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Pembaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Gracia-Batllori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Par\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adri\u00e0","family":"D\u00edaz-Permanyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pau","family":"Brugada-Vil\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Fornaguera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Cascante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvador","family":"Borr\u00f3s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Kreppel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Fillat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2026.115320_bb0005","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1016\/j.ymthe.2025.03.035","article-title":"Oncolytic viruses as cancer therapeutics: from mechanistic insights to clinical translation","volume":"33","author":"Alwithenani","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2026.115320_bb0010","article-title":"Oncolytic adenovirus: prospects for cancer immunotherapy","volume":"12","author":"Zhao","year":"2021","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.jconrel.2026.115320_bb0015","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ccell.2025.03.010","article-title":"The discrete charm of oncolytic viruses: toward the finish line","volume":"43","author":"Lowenstein","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jconrel.2026.115320_bb0020","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010016","article-title":"First-in-human clinical outcomes with NG-350A, an anti-CD40 expressing tumor-selective vector designed to remodel immunosuppressive tumor microenvironments","volume":"12","author":"Naing","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.jconrel.2026.115320_bb0025","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-024-03219-0","article-title":"Single intravenous administration of oncolytic adenovirus TILT-123 results in systemic tumor transduction and immune response in patients with advanced solid tumors","volume":"43","author":"Jirovec","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115320_bb0030","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1517\/17425247.2014.938637","article-title":"The importance of coagulation factors binding to adenovirus: historical perspectives and implications for gene delivery","volume":"11","author":"Lopez-Gordo","year":"2014","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2026.115320_bb0040","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc6659","article-title":"Systemic cancer therapy with engineered adenovirus that evades innate immunity","volume":"12","author":"Atasheva","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2026.115320_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113822","article-title":"Formulation-optimized oncolytic viruses: advancing systemic delivery and immune amplification","volume":"383","author":"Ma","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115320_bb0050","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1056\/NEJMoa2202028","article-title":"Oncolytic DNX-2401 virus for pediatric diffuse intrinsic pontine glioma","volume":"386","author":"G\u00e1llego P\u00e9rez-Larraya","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2026.115320_bb0055","article-title":"Emerging delivery strategy for oncolytic virotherapy","volume":"32","author":"Zhu","year":"2024","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.jconrel.2026.115320_bb0060","article-title":"Oncolytic virotherapy: basic principles, recent advances and future directions","volume":"8","author":"Lin","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2026.115320_bb0065","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jconrel.2021.02.018","article-title":"Overcoming the barriers to optimization of adenovirus delivery using biomaterials: current status and future perspective","volume":"332","author":"Kasala","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115320_bb0070","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jconrel.2008.12.009","article-title":"Coating of adenovirus type 5 with polymers containing quaternary amines prevents binding to blood components","volume":"135","author":"Subr","year":"2009","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115320_bb0075","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jconrel.2016.06.022","article-title":"Substitution of blood coagulation factor X-binding to Ad5 by position-specific PEGylation: preventing vector clearance and preserving infectivity","volume":"235","author":"Krutzke","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115320_bb0080","doi-asserted-by":"crossref","DOI":"10.1080\/10717544.2025.2494775","article-title":"PEGylation technology: addressing concerns, moving forward","volume":"32","author":"Simberg","year":"2025","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2026.115320_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2026.115925","article-title":"Anti-PEG antibodies in nanomedicine: mechanisms, risks, and opportunities","volume":"236","author":"Mihindukulasooriya","year":"2026","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.115320_bb0090","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201900849","article-title":"In vivo retargeting of poly(beta aminoester) (OM-PBAE) nanoparticles is influenced by protein corona","volume":"8","author":"Fornaguera","year":"2019","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.jconrel.2026.115320_bb0095","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.7150\/thno.40902","article-title":"Oligopeptide-modified poly(beta-amino ester)s-coated AdNuPARmE1A: boosting the efficacy of intravenously administered therapeutic adenoviruses","volume":"10","author":"Brugada-Vil\u00e0","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2026.115320_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102786","article-title":"Patient-derived pancreatic tumour organoids identify therapeutic responses to oncolytic adenoviruses","volume":"56","author":"Raimondi","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jconrel.2026.115320_bb0105","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/mt.2008.307","article-title":"Redundant and synergistic mechanisms control the sequestration of blood-born adenovirus in the liver","volume":"17","author":"Di Paolo","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2026.115320_bb0110","doi-asserted-by":"crossref","first-page":"10914","DOI":"10.1128\/JVI.05382-11","article-title":"A cluster of basic amino acids in the factor X serine protease mediates surface attachment of adenovirus\/FX complexes","volume":"85","author":"Duffy","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.jconrel.2026.115320_bb0115","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/gt.2011.87","article-title":"Coagulation factor X mediates adenovirus type 5 liver gene transfer in non-human primates (Microcebus murinus)","volume":"19","author":"Alba","year":"2012","journal-title":"Gene Ther."},{"key":"10.1016\/j.jconrel.2026.115320_bb0120","doi-asserted-by":"crossref","first-page":"11705","DOI":"10.1128\/JVI.01320-08","article-title":"Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complement","volume":"82","author":"Xu","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.jconrel.2026.115320_bb0125","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/mt.2010.229","article-title":"Modifications of adenovirus hexon allow for either hepatocyte detargeting or targeting with potential evasion from Kupffer cells","volume":"19","author":"Prill","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2026.115320_bb0130","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1128\/JVI.05760-11","article-title":"Identification of adenovirus serotype 5 hexon regions that interact with scavenger receptors","volume":"86","author":"Khare","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.jconrel.2026.115320_bb0135","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1016\/j.biomaterials.2010.10.031","article-title":"Active targeting and safety profile of PEG-modified adenovirus conjugated with herceptin","volume":"32","author":"Kim","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2026.115320_bb0140","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-26030-3","article-title":"Effects of pre-existing anti-adenovirus antibodies on transgene expression levels and therapeutic efficacies of arming oncolytic adenovirus","volume":"12","author":"Ono","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2026.115320_bb0145","article-title":"KPC pancreatic cancer cells are a novel immunocompetent murine model supporting human adenovirus replication and tumor oncolysis","volume":"33","author":"Otero-Mateo","year":"2024","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.jconrel.2026.115320_bb0150","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1158\/0008-5472.CAN-17-1882","article-title":"Zeb1 in stromal myofibroblasts promotes Kras-driven development of pancreatic cancer","volume":"78","author":"Sangrador","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115320_bb0155","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ymthe.2018.09.016","article-title":"Bioselection reveals miR-99b and miR-485 as enhancers of adenoviral oncolysis in pancreatic cancer","volume":"27","author":"Rovira-Rigau","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2026.115320_bb0160","doi-asserted-by":"crossref","first-page":"22700","DOI":"10.18632\/oncotarget.15169","article-title":"A NOTCH-sensitive uPAR-regulated oncolytic adenovirus effectively suppresses pancreatic tumor growth and triggers synergistic anticancer effects with gemcitabine and nab-paclitaxel","volume":"8","author":"Mato-Berciano","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jconrel.2026.115320_bb0165","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/gt.2014.52","article-title":"iRGD tumor-penetrating peptide-modified oncolytic adenovirus shows enhanced tumor transduction, intratumoral dissemination and antitumor efficacy","volume":"21","author":"Puig-Saus","year":"2014","journal-title":"Gene Ther."},{"key":"10.1016\/j.jconrel.2026.115320_bb0170","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2144\/000112993","article-title":"Re-engineering adenovirus vector systems to enable high-throughput analyses of gene function","volume":"45","author":"Stanton","year":"2008","journal-title":"Biotechniques"},{"key":"10.1016\/j.jconrel.2026.115320_bb0175","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1038\/sj.gt.3301515","article-title":"CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors","volume":"8","author":"Alemany","year":"2001","journal-title":"Gene Ther."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926007248?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926007248?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:20:03Z","timestamp":1793337603000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926007248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":34,"alternative-id":["S0168365926007248"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115320","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Position-specific polymeric-coated oncolytic adenovirus improves anti-tumor efficacy and evades neutralizing antibodies in pancreatic cancer models","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115320","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115320"}}